<!DOCTYPE html>
<html>
    <head>
        <title>§ 28-4552 Definitions.</title>
        <meta http-equiv='content-type' content='text/html; charset=utf-8' />
        <link rel='stylesheet' media='screen' type='text/css' href='/simple-2012/css/base.css' />
    </head>
    <body>
        <div class='alert'>
            <a href='http://dccode.org/simple/sections/28-4552.html'>this is an outdated text: switch to the updated &amp; improved dc code website</a>
        </div>
        <header>
            <div class='right'>
                <a href='/simple-2012/'>home</a>,
                <a href='about.html'>about</a>
            </div>
            <h1>The DC Code: § 28-4552 Definitions.</h1>
            <a href='../'>Index</a> &rarr; <a href='../28.html'>28 Commercial Instruments and Transactions. (Refs & Annos)</a>
        </header>
        
            
                <p>For the purposes of this chapter, the term:</p>
            
        

        
        <dl>
            
                <dt>1</dt>
                <dd> "Affected party" means any person directly or indirectly affected by excessive prices of patented prescription drugs, including any organization representing such persons or any person or organization representing the public interest.</dd>
            
                <dt>2</dt>
                <dd> "High income country" means the United Kingdom, Germany, Canada, or Australia.</dd>
            
        </dl>
        

        
        <h3>Historical and Statutory</h3>
        <p>Legislative History of Laws

For Law 16-37, see notes following <a href='./28-4551.html'>§ 28-4551</a>.

DC CODE <a href='./28-4552.html'>§ 28-4552</a>

Current through December 11, 2012</p>
        

        
        <h3>Credits</h3>
        <p>(Dec. 10, 2005, D.C. Law 16-37, § 2, 52 DCR 9061.)

GENERAL NOTES

This chapter has been held unconstitutional in the case of Pharmaceutical Research and Mfrs. of America v. District of Columbia, 2005, 406 F.Supp.2d 56, 78 U.S.P.Q.2d 1822, affirmed 496 F.3d 1362, 83 U.S.P.Q.2d 1639, rehearing and rehearing en banc denied 505 F.3d 1343, 85 U.S.P.Q.2d 1144.</p>
        
    </body>
</html>
